SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARIAD Pharmaceuticals
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
4474 134 0 ARIA
Emcee:  jaybe Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4349Yes, you might have to fight with the insurer to get coverage. CVS just dropped Biomaven-8/3/2016
4348BioM, if the doctors use it in first line setting and the company agrees with tjesspro-8/3/2016
4347For a front-line label you have to conduct a trial and get FDA to agree to the rBiomaven-8/3/2016
4346Jaybe, I have a question for you. Can a second line drug be promoted to first lijesspro-8/3/2016
4345Word getting out about briga: “CNS penetration may be the game changer for the Biomaven37/26/2016
4344Thank you jaybe! Jesspro has been posting a number of false assumptions on othertktom-7/23/2016
4343thanks...jesspro-7/22/2016
4342OPTIC is limited to patients with at least two prior TKIs, so while good resultsjaybe17/22/2016
4341Jaybe, in the OPTIC trials (not OPTIC-2L), what happens if for the sake of discujesspro-7/22/2016
4340Update on move to new HQ at 125 Binney Street... bostonglobe.comjaybe-7/16/2016
4339I'd hope there would be a larger placebo controlled trial in one of the neurghmm-7/13/2016
4338MD Anderson launches pona trial for AML... Pretty extensive IST, 132 patients, jaybe-7/12/2016
433724 months is pretty far out, but would capture everything mentioned at Analyst Djaybe-7/12/2016
4336Jaybe, in the event Ariad is not sold in the next 24 months, what do you think ajesspro-7/12/2016
4335Weathering the CAR T Storm: JUNO- KITE- BLUE Could the disappointing event wittktom-7/8/2016
4334More details about valuation of Ariad Europe can be found in Incyte's 8-K/A.jaybe-7/2/2016
4333Update on status of Spirit3 trial in UK... "You may be aware that Ariad’s jaybe-7/2/2016
4332Yes, that article (which is new to me) does indeed suggest the possibility that Biomaven-6/30/2016
4331GHF/Peter, do they have a case here when they suggested that ponatinib did not pjesspro-6/30/2016
4330Looks like Biomaven got a pithy response in while I was typing away. Good.glass 0.5 full-6/30/2016
4329I will be interested to hear. My recollection was that pona was not only activeglass 0.5 full-6/30/2016
4328>>does ponatinib cross the BBB? Yes.Biomaven-6/30/2016
4327Jaybe, does ponatinib cross the BBB?jesspro-6/30/2016
4326Maybe they tried and were met with a different form of resistance...in HB. In ajaybe-6/23/2016
4325It's a great pity that nobody seems to have followed up on that Genentech paBiomaven-6/23/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News